Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Yielding 0.8% – But Is It A Buy?

Dividend paying stocks like Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) tend to be popular with investors, and for good reason – some research suggests a significant amount of all stock market returns come from reinvested dividends. If you are hoping to live on your dividends, it’s important to be more stringent with your investments than the average punter. Regular readers know we like to apply the same approach to each dividend stock, and we hope you’ll find our analysis useful.

A 0.8% yield is nothing to get excited about, but investors probably think the long payment history suggests Sun Pharmaceutical Industries has some staying power. Remember though, due to the recent spike in its share price, Sun Pharmaceutical Industries’s yield will look lower, even though the market may now be factoring in an improvement in its long-term prospects. Some simple analysis can offer a lot of insights when buying a company for its dividend, and we’ll go through this below.

Explore this interactive chart for our latest analysis on Sun Pharmaceutical Industries!

NSEI:SUNPHARMA Historical Dividend Yield June 17th 2020
NSEI:SUNPHARMA Historical Dividend Yield June 17th 2020

Payout ratios

Companies (usually) pay dividends out of their earnings. If a company is paying more than it earns, the dividend might have to be cut. So we need to form a view on if a company’s dividend is sustainable, relative to its net profit after tax. Sun Pharmaceutical Industries paid out 25% of its profit as dividends, over the trailing twelve month period. This is a medium payout level that leaves enough capital in the business to fund opportunities that might arise, while also rewarding shareholders. Besides, if reinvestment opportunities dry up, the company has room to increase the dividend.

In addition to comparing dividends against profits, we should inspect whether the company generated enough cash to pay its dividend. Sun Pharmaceutical Industries paid out a conservative 28% of its free cash flow as dividends last year. It’s encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don’t drop precipitously.

With a strong net cash balance, Sun Pharmaceutical Industries investors may not have much to worry about in the near term from a dividend perspective.

Remember, you can always get a snapshot of Sun Pharmaceutical Industries’s latest financial position, by checking our visualisation of its financial health.

Dividend Volatility

Before buying a stock for its income, we want to see if the dividends have been stable in the past, and if the company has a track record of maintaining its dividend. For the purpose of this article, we only scrutinise the last decade of Sun Pharmaceutical Industries’s dividend payments. Its dividend payments have declined on at least one occasion over the past ten years. During the past ten-year period, the first annual payment was ₹1.38 in 2010, compared to ₹4.00 last year. Dividends per share have grown at approximately 11% per year over this time. Sun Pharmaceutical Industries’s dividend payments have fluctuated, so it hasn’t grown 11% every year, but the CAGR is a useful rule of thumb for approximating the historical growth.

Sun Pharmaceutical Industries has grown distributions at a rapid rate despite cutting the dividend at least once in the past. Companies that cut once often cut again, but it might be worth considering if the business has turned a corner.

Dividend Growth Potential

With a relatively unstable dividend, it’s even more important to evaluate if earnings per share (EPS) are growing – it’s not worth taking the risk on a dividend getting cut, unless you might be rewarded with larger dividends in future. Over the past five years, it looks as though Sun Pharmaceutical Industries’s EPS have declined at around 3.6% a year. Declining earnings per share over a number of years is not a great sign for the dividend investor. Without some improvement, this does not bode well for the long term value of a company’s dividend.

Conclusion

Dividend investors should always want to know if a) a company’s dividends are affordable, b) if there is a track record of consistent payments, and c) if the dividend is capable of growing. It’s great to see that Sun Pharmaceutical Industries is paying out a low percentage of its earnings and cash flow. Second, earnings per share have been in decline, and its dividend has been cut at least once in the past. In sum, we find it hard to get excited about Sun Pharmaceutical Industries from a dividend perspective. It’s not that we think it’s a bad business; just that there are other companies that perform better on these criteria.

It’s important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. However, there are other things to consider for investors when analysing stock performance. As an example, we’ve identified 2 warning signs for Sun Pharmaceutical Industries that you should be aware of before investing.

If you are a dividend investor, you might also want to look at our curated list of dividend stocks yielding above 3%.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.